Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis
Clinical Gastroenterology and Hepatology · 2023-02 · 21 (2) · 456-466.e7
DOI: 10.1016/j.cgh.2022.07.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-02. Verfasst von Parambir S Dulai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address: parambir.du…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Feces, Leukocyte L1 Antigen Complex. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND & AIMS: We evaluated the value of post-induction fecal calprotectin (FCP) concentration as a biomarker in patients with ulcerative colitis (UC) treated with a biologic. METHODS: This post hoc analysis of the GEMINI 1/GEMINI LTS (N = 620) and VARSITY (N = 771) trials evaluated the cross-sectional accuracy of post-induction FCP in identifying endoscopic activity and histologic inflammation, and the prognostic performance of FCP in identifying patients most likely to achieve endoscopic and histologic remission or require colectomy and UC-related hospitalization. RESULTS: The cross-sectional accuracy of FCP in identifying endoscopic activity and histologic inflammation was modest (63%-79%). However, a post-induction FCP concentration of ≤250 μg/g vs >250 μg/g was associated with a substantially higher probability of achieving clinical remission (odds ratio [OR], 4.03; 95% confidence interval [CI], 2.78-5.85), endoscopic remission (OR, 4.26; 95% CI, 2.83-6.40), and histologic remission (Robarts Histopathology Index: OR, 5.54; 95% CI, 3.77-8.14; Geboes grade: OR, 6.42; 95% CI, 4.02-10.26) at week 52 and a lower probability of colectomy over 7 years (hazard ratio, 0.296; 95% CI, 0.130-0.677) and UC-related hospitalization (hazard ratio, 0.583; 95% CI, 0.389-0.874). The association with colectomy was significant even among patients in symptomatic remission or with endoscopic improvement post-induction, and among patients with elevated FCP at baseline. CONCLUSIONS: Although FCP had only modest cross-sectional accuracy in identifying disease activity, an FCP concentration of ≤250 μg/g vs >250 μg/g was associated with increased probability of achieving long-term clinical, endoscopic, and histologic remission, and reduced probability of colectomy and UC-related hospitalization (ClinicalTrials.gov: NCT00783718, NCT00790933, NCT02497469).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address: parambir.dulai@northwestern.edu.
- Robarts Clinical Trials, Western University, London, Ontario, Canada.
- Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
- Statistics and Quantitative Sciences, Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
- US Medical Office, Takeda Pharmaceuticals U.S.A Inc., Lexington, Massachusetts.
- Clinical Science, Takeda Development Center Americas, Inc., Cambridge, Massachusetts.
Zitieren
APA
Dulai, P. S., Feagan, B. G., Sands, B. E., Chen, J., Lasch, K., & Lirio, R. A. (2023). Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 21(2), 456-466.e7. https://doi.org/10.1016/j.cgh.2022.07.027
Vancouver
Dulai PS, Feagan BG, Sands BE, Chen J, Lasch K, Lirio RA. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2023;21(2):456-466.e7. doi:10.1016/j.cgh.2022.07.027
BibTeX
@article{Dulai2023,
author = {Dulai, Parambir S and Feagan, Brian G and Sands, Bruce E and Chen, Jingjing and Lasch, Karen and Lirio, Richard A},
title = {Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
volume = {21},
number = {2},
pages = {456--466.e7},
doi = {10.1016/j.cgh.2022.07.027}
}
EUVIMED